Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Impedimed Limited ( (AU:IPD) ) is now available.
ImpediMed Limited reported a record Total Contract Value (TCV) of $6.3 million for its SOZO Core Business in Q4 FY25, driven by enhanced sales strategies and leadership. The company sold 44 SOZO units in the US, including a significant contract with Legacy Health, while no units were sold internationally due to distributor restocking schedules. Despite a slight revenue decline to $3.3 million, the company maintained strong annual recurring revenue growth and reduced its cash cost base by 16% compared to FY24. ImpediMed’s financial position remains robust with a cash balance of $22.2 million, positioning it well for future growth.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on non-invasive medical devices. Its primary product, the SOZO device, is used for monitoring and managing fluid status and body composition, with a significant market focus on the healthcare sector, including hospitals and clinics.
Average Trading Volume: 2,737,954
Technical Sentiment Signal: Hold
Current Market Cap: A$105.4M
See more data about IPD stock on TipRanks’ Stock Analysis page.